The FDA on August 17, 2015 approved ADCETRIS® for the post-autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) consolidation treatment of patients with classical Hodgkin Lymphoma (HL) at high risk of relapse or progression. ADCETRIS® is a product of Seattle Genetics, Inc.
Bottom Ad
Advertisement
Subscribe
